The therapeutic promise of small RNA therapeutics (siRNAs, miRNAs) is not only limited by the lack of delivery vehicles, but also by the inability of the small RNAs to reach intracellular compartments where they can be biologically active. We previously reported successful delivery of functionally active miRNAs via receptor-mediated endocytosis 1 . This type of targeted therapy still faces one of the major challenges in the delivery field, endosomal sequestration. Here, a new method has been developed to promote endosomal escape of delivered miRNA. The strategy relies on the difference in solute contents between nascent endosomes and the cytoplasm: early endosomes are rich in sodium ions (Na + ) while the intracellular fluid is rich is potassium ions (K + ). Exploiting this difference through favoring the influx of K + into the endosomes without the exchange for a osmotically active ion (Na + ), results in an osmotic differential leading to endosome swelling and bursting. One molecule that is able to exchange K + for an osmotically inactive hydrogen ion is the ionophore nigericin. Via generating an intramolecular miRNA delivery vehicle, containing a ligand, in this case folate, and nigericin we achieve escape of folate-RNA conjugates (e.g. FolamiRs) from their entrapping endosomes into the cytoplasm where they bind the RNA Induced Silencing complex (RISC) and activate the RNAi response.
Introduction
The therapeutic prospect of miRNA replacement therapies relies on reintroducing small synthetic RNA molecules that mimic endogenous miRNAs in cells that have lost them with the final goal of restoring cellular pathways that could stop pathogenesis. However, a major constraint in the transition of miRNA mimics, and other small RNAs (small interfering RNA, siRNA; antisense oligonucleotides), into the clinic has been the lack of efficient delivery systems. Encapsulation of small RNAs, for instance, has had mixed results in the clinic with clinical trials showing toxicity and limited efficacy 2 . Some problems that come with the use of encapsulating delivery vehicles (e.g. liposomes, micelles, polymers) include delivery-associated toxicity, poor transfection efficiency, and nonspecific biodistribution 3 .
Our previous work shows that these vehicle-related defects may be overcome by eliminating the vehicle, attaching a miRNA to a folate ligand (FolamiR) 1 . This approach can deliver functionally active miRNAs to cancer cells that overexpress the folate receptor (FR) via receptor-mediated endocytosis with no signs of toxicity (maximum tolerated dose >26.64 mg/kg) 1 . Thus, in the absence of toxicity, the main factors limiting dosage would be two-fold: i) the internalization kinetics of the folate-ligand bound to its receptor (endocytosis) and ii) the rate by which the FolamiR can escape the endosome 4, 5 .
We reasoned that since the internalization kinetics of FolamiRs are less amendable and already rapid [6] [7] [8] , the development and inclusion of an endosomal escape mechanism onto nextgeneration FolamiRs could help overcome the rate-limiting step of endosomal escape providing higher efficacy, and further reducing toxicity. Endosomal escape of small RNAs (and other biologics) has been recognized as a major hindrance in the path to translating RNA therapeutics into the clinic. For that reason efforts have been focused on developing strategies to enhance endosomal release and secure cytosolic delivery 9 . Proteins and peptide-based agents (i.e. cell penetrating peptides, CPPs) are often used to achieve cytosolic release of oligonucleotides 9 .
For instance, the EB1 peptide, derived from penetratin, is a CPP with endosomolytic properties that facilitates transport of active siRNAs into cells 10 . Similarly, the inclusion of influenza-derived fusogenic peptide diINF-7 has been shown to enhance endosomal escape of siRNAs when complexed with lipid carriers 11 . However, the use of peptides is often toxic and may contribute to increased immunogenicity 12 , which is already a major concern in RNA therapeutics. Another approach to improve endosomal release of nucleic acids is the use of "proton sponges" that can promote endosomal swelling by inducing counterion uptake that leads to increased osmotic pressure 13 . The practicality of using this strategy in the clinic is dampened due to the large concentration of compound needed to achieve efficient endosomal bursting 13 . Photochemical internalization (PCI) is another alternative to increase endosomal escape of siRNAs, but this approach is greatly limited to specific sites where light can be used to trigger endosome lysis, which reduces its practical use in the clinic 14 .
We recently described a novel method to facilitate the escape of biologics from entrapping endosomes and in that study provided preliminary evidence for the potential use of this method to improve the escape of small RNAs from endosomes 15 . The strategy relies on the difference in solute contents between nascent endosomes and the cytoplasm: endosomes are rich in sodium ions (Na + ) while the intracellular fluid is rich is potassium ions (K + ). The method exploits this difference by using a small molecule, nigericin 16, 17 , that exchanges K + for osmotically inactive proton (H + ) to achieve balance in charge without release of a compensatory solute (Na + ) thus causing a osmotic differential that leads to endosome swelling and bursting 15 .
Herein, we show that this approach is useful to overcome endosomal entrapment of small RNAs delivered by folate. The data presented here suggest that ligand-targeted delivery of nigericin into endosomes can facilitate the escape of RNA cargo (e.g. miRNAs, siRNAs) from their entrapping endosomes, helping the small RNAs to become available in the cytoplasm, engage the RNA Induced Silencing complex (RISC) and improve their RNAi activity (see proposed model in Figure 1 ). Developing a highly specific delivery platform (i.e. FolamiRs) with increased endosomolytical properties could be useful towards achieving significant therapeutic effects at low concentrations and without unwanted toxicity for future in vivo applications.
Results
Folate-nigericin-miRNA conjugation and stability in serum
Since nigericin needs to dissociate from the folate carrier and localize to the endosomal membrane to induce endosome swelling (exchange intracellular K + for H + ), an intramolecular disulfide linkage was incorporated between nigericin and the folate-RNA conjugate ( Figure 2A ).
Folate-nigericin-miRNA conjugation was achieved as previously described 1 by using click chemistry 26 and conjugation was verified by polyacrylamide gel electrophoresis (PAGE) analysis ( Figure 2B ) and matrix-assisted laser desorption/ionization (MALDI) spectral analysis (not shown). Disulfide linkage reduction was verified by PAGE analysis by a band size shift upon tris(2-carboxyethyl)phosphine (TCEP) treatment ( Figure 2B ). To test the stability of the disulfide linkage, Fol-Nig-34a compounds were exposed to 50% serum. No signs of Fol-Nig-34a reduction were observed for more than four hours ( Figure 2C ) leaving open the possibility that premature reduction upon systemic delivery could occur after 4 h. Our previous results using FolamiRs in vivo show that less than four hours is enough time for the folate conjugates to localize and be internalized into the intended tissues 1 .
Folate-nigericin-miRNA conjugate uptake is mediated by the folate receptor Due to the high affinity of the ionophore nigericin for cellular membranes it was important to verify that uptake of Fol-Nig-miRNA conjugates was mediated by the FR. For that purpose, expression of the FR in MB-231 cells and KB cells was verified by flow cytometric analyses as previously reported 1,27 using a folate-cyanine 5 conjugate (Fol-Cy5; Figure 3A ). Next, to visualize cellular uptake of miR-34a in the absence or presence of nigericin, an Atto-647N fluorophore was attached to the 5′ end of miR-34a-5p strand generating Fol-34a-Atto647N and Fol-Nig-34a-Atto647N. Specificity of cellular uptake of Fol-34a-Atto647N or Fol-Nig-34a-Atto647N conjugates was conducted in the presence or absence of folate glucosamine as a competitor ( Figure 3B ,C). Both conjugates were taken up by MB-231 and KB cells only in the absence of folate glucosamine suggesting that the uptake is FR mediated. Furthermore, minimal uptake in the absence of folate conjugation (gymnotic uptake) was observed ( Figure   3D , duplex miR-34a-Atto647N). Taken together these results suggest that Fol-Nig-miRNA uptake is mediated by the FR.
Ligand-targeted delivery of nigericin causes endosomal release of miR-34a
To track the release of cargo from endosomes, cyanide 5 (Cy5) was delivered either with a folate-only or a folate-nigericin carrier, and the fluorescent cellular distribution was used as a surrogate for cargo localization. Ligand-targeted delivery of nigericin promotes miR-34a targeting and engagement in RISC To validate that nigericin can mediate endosomal escape, we used a functional assay to monitor
RNAi activity using miR-34a. Luciferase reporter assays were performed in MB-231 cells that express a reporter for miR-34a 1 . Renilla level in these cells is inversely correlated with miR-34a activity. These cell-based experiments indicated a rapid reduction in luciferase activity in FolNig-34a treated cells as soon as 18h post treatment (reaching ∼ 40% knockdown) and after 48h reaching 85% ( Figure 5A ). This reduction in luciferase activity did not occur via gymnosis (see Figure 5A , gray bars) nor was it observed in Fol-Nig-NC treated cells suggesting that the effect is specific to the presence of miR-34a and not due to a side effect caused by potential nigericin mediated toxicity. To eliminate that possibility, we conducted cellular toxicity assays and the results show that the first signs of toxicity related to nigericin compounds (folate-nigericin) can be visualized at concentrations >1000nM ( Figure 5B) , well above the 50 nM concentration used for the functional assays. Next, we reasoned that since RNA-induced silencing complex (RISC) programming is triggered by the appearance of double stranded RNA in the cytoplasm (i.e. miRNA) and Ago proteins localize diffusely in the cytoplasm and nucleus 28, 29 loading of miR34a-5p into Ago would be indicative of cytosolic release. We first tested if Fol-Nig-34a activity is mediated by Ago proteins by measuring cell proliferation when Ago2 is knocked down ( Figure   5C ). The results show that Fol-Nig-34a only reduces cellular proliferation when Ago2 is present, indicating that Fol-Nig-34a cellular effects are mediated in part by the RNAi pathway. These results were also reproducible using a Fol-Nig-siRNA conjugate against Ras homolog gene family, member A (siRhoA), a known target that affects cell proliferation in MB-231 breast cancer cells 18 ( Figure 5D ). To further test the hypothesis that nigericin facilitates the release of RNA cargo into the cytoplasm, we performed RNA immunoprecipitation (RIP) assays by immunoprecitating Argonaute (Ago) proteins 21, 22 in cells treated with FolamiR-34a or Fol-Nig34a ( Figure 5E ). The results show that miRNA-34a-5p is more abundant in Ago RIP following folate-nigericin delivery (∼6 fold) compared to delivery using the folate-only conjugation ( Figure   5F , compare blue bar to red bar in miR-34a qRT lanes). Ago did not pull down RNU6B, as expected, but was associated with the positive control let-7b validating the assay. Taken together, these results support the hypothesis that partial decrease in luciferase activity is RNAi mediated and that the inclusion of nigericin in the folate carrier can help miR-34a escape from endosomes and become available in the cytoplasm to associate with Ago.
Inclusion of nigericin in the folate carrier enhances miRNA activity
To test the hypothesis that the incorporation of nigericin in the folate carrier can lead to enhanced miR-34a activity in culture time-response studies were conducted comparing FolamiR-34a and Fol-Nig-34a. The results show a difference in luciferase repression between FolamiR-34a (~30% reduction in Renilla activity) and Fol-Nig-34a (~85% reduction in Renilla activity, Figure 6A ) that could indicate that FolamiR-34a gets entrapped inside endosomes by folate-targeted endocytosis. This could also explain why miR-34a delivered by folate alone is not abundant in Ago RIP ( Figure 5F ). Similarly, delivery of siRhoA by folate-nigericin results in higher anti-proliferative activity compare to delivery using the folate-only carrier ( Figure 6B ).
To verify that the released miR-34a can repress endogenous targets, MB-231 cells were exposed to FolamR-34a or Fol-Nig-34a and surface expression of PD-L1, a miR-34a target was monitored by flow cytometry. Only in the presence of Fol-Nig-34a was PD-L1 downregulated ( Figure 6C ). The effect observed was nearly identical to downregulation of PD-L1 following transfection of miR-34a mimics. Importantly, there was no reduction in PD-L1 in FR negative A549 cells ( Figure 6D ), unless cells were transfected with miR-34a mimics, suggesting dependency of the FR on this response. This dependency was verified in MB-231 cells, where excess folate-glucosamine mitigated the effect ( Figure 6E ). Taken together, these results support the hypothesis that rapid release of miRNA cargo from endosomal vesicles mediated by nigericin can improve miR-34a activity in culture.
Discussion
Development of an effective delivery strategy for targeted, tissue-specific delivery of small RNAs can be achieved with the use of small ligands. The addition of a ligand to a small RNA promotes its cellular uptake and trafficking, and although is a key advantage to achieve the required specific biodistribution, it often suffers from a major limitation, endosomal entrapment. Upon binding to the membrane receptor, these ligands and the associated RNA cargo are internalized by receptor-mediated endocytosis and loaded into early endosomes. The contents of the endocytic vesicles are then sorted and trafficked intracellularly en route to the lysosome, which is where the nucleic acid cargo will be degraded or are recycled back to the extracellular space.
To avoid these therapeutically limiting effects, the ligand-RNA conjugates need to escape from the endosome into the cytoplasm where they can engage RISC and modulate gene expression.
Thus, the clinical application of small RNA therapeutics requires the development of delivery strategies that not only can direct tissue-specific internalization, but also effectively traffic the small RNA to the cytoplasm reaching biologically relevant doses.
Our previous research showed that it is possible to deliver a miRNA mimic to cancerous cells by simply conjugating the passenger strand to a folate ligand with no signs of toxicity at the therapeutic dose tested 1 . Because folate conjugates are internalized via endocytosis, endosomal sequestration could be a limiting step in achieving significant clinical effects. We reasoned that the inclusion of an inter-molecular endosomal escape mechanism could ensure robust cytosolic delivery of the RNA cargo and lead to enhanced miRNA activity. This approach relies on the use of a small molecule, nigericin, that upon cellular internalization gets cleaved from the folate carrier and localizes to endosomal membrane where it exchanges K + and water for osmotically inactive proton (H + ) causing endosomal swelling 15 . To be effective, nigericin release has to occur in a controlled manner and only within the endosomes. Our preliminary evidence suggest that folate-nigericin-miRNA molecules are stable in 50% serum for at least four hours, which according to our previous observations would be enough time for the conjugate to be internalized into the target cells 1 . Premature cleavage and release of nigericin in circulation is a concern and further in vivo experiments will be needed to evaluate this possibility.
The evidence presented here supports that the new method for endosomal release of small RNAs can be advantageous therapeutically. The aims of this strategy are to decrease the dosage of mimics needed to achieve effective gene modulation and minimize unwanted toxicity.
The data support that ligand-targeted delivery of nigericin into endosomes can facilitate the escape of RNA cargo (e.g. miRNAs, siR-NAs) from their entrapping endosomes, helping the small RNAs to become available in the cytoplasm, engage the RNA-Induced Silencing complex (RISC) and improve their RNAi activity. Thus, it is possible that with the help of nigericin, therapeutically relevant small RNAs could be delivered at low quantities and still show effective targeting. The most clinically advanced ligand-siRNAs, GalNAc-siRNA conjugates [30] [31] [32] [33] [34] , have
shown mixed results and often require very high doses to achieve a significant biological effect.
It is too early to know if the high doses of these oligonucleotides will have deleterious effects in the patients. Perhaps, achieving lower effective doses of therapeutic RNAs could be the key to avoid in vivo toxicity.
We anticipate that since nigericin is a small molecule, nontoxic, and easy to conjugate to a small RNA using a variety of self-cleavable linkers it will be easy to translate into the clinic. The challenge of the field of small RNA delivery is to continue to design and optimize delivery mechanism at all stages, from the delivery process, to cytosolic release, to uptake into RISC and mRNA cleavage such that small RNAs can be delivered to the intended tissues at low effective doses in the absence of unwanted toxicity. There is scientific awareness about the potential of miRNA therapeutics, but with the lack of effective cytosolic release strategies small RNA therapeutics are predetermined to bottleneck in the clinic. Although these molecules have yet to reach in vivo experiments, the rigorous understanding of the safety and efficacy profiles of this new delivery and release platform could eventually enable the transition of ligand-RNA conjugates from the bench to the bedside. Preparation of folate-nigericin-DBCO-miR-34a (Fol-Nig-34a) conjugate
Materials and methods

Cell
MiRNA duplexes were constructed as previously described 1 . Briefly, a bi-orthogonal click reaction was performed between folate-nigericin-DBCO and azide modified antisense miR-34a
(or scramble). Click reaction was performed at a 1:10 molar ratio (azide oligo: folate-nigericin-DBCO) at room temperature in water for eight hours and then cooled to 4°C for four hours.
Unconjugated folate-nigericin-DBCO was removed from the reaction using Oligo Clean and Concentrator (Zymo Research) per manufacturer instructions. Conjugation was verified using 15% TAE native polyacrylamide gel electrophoresis (PAGE) and MALDI spectral analysis. After conjugation, the miR-34a sense strand was annealed to the folate-nigericin-miR-34a antisense conjugate. Folate-nigericin-DBCO-miR-34a antisense and miR-34a sense were mixed in an equal molar ratio (1:1, final concentration, 20 uM each) in annealing buffer: 10 mM Tris buffer, pH 7 (Sigma), supplemented with 50 mM NaCl (Sigma), and 1 mM EDTA (Sigma), and incubated at 95°C for five min, cooled slowly to room temperature and then stored at -80°C.
This compound is referred to as Fol-Nig-34a. For siRNA studies, the previously reported oligonucleotides targeting Ras homolog gene family, member A (siRhoA) 18 were used: sense 5'-GACAUGCUUGCUCAUAGUCTT-3', antisense 3'-TTCUGUACGAACGAGUAUCAG-5'. For cellular uptake experiments, an Atto-647N fluorophore was attached to the 5′ end of the miR-34
antisense oligo and was used in the annealing step generating the following compounds: Fol34a-Atto647N, and Fol-Nig-34a-Atto647N.
Stability assay in serum
Stability assays were performed as previously described 1 . Briefly, Fol-Nig-34a conjugates were incubated in 50% fetal bovine serum (Sigma) in water at 37°C for the indicated times. RNA samples were collected and analyzed using 15% TAE PAGE. The reducing agent tris(2-carboxyethyl)phosphine (TCEP) was used as a positive control for nigericin reduction (5mM, 20 min at room temperature).
Preparation of folate-cyanide 5 (Fol-Cy5) dye conjugate Folate-cyanide 5 synthesis was performed as previously described 15 . DIPEA (0.0004 g, 0.0032 mmol, 2 eq.) was added dropwise to a stirred solution of folate-EDA (0.0008 g, 0.0016 mmol, 1 eq.) and NHS-Cyanide 5 (Cy5, 0.001 g, 0.001 mmol, 1.1 eq.) in DMSO. The reaction mixture continued to be stirred at room temperature. Progress of the reaction was monitored by LC-MS.
After complete conversion of folate-Cy5, the crude reaction mixture was purified by RP-HPLC.
(mobile phase A = 10 mM ammonium acetate, pH = 7; organic phase B = acetonitrile; method: 0% B to 50% B in 35 min at 13 ml/min) and furnished folate-Cy5 dye conjugate in 85% yield. 
LC-MS (
RNA immunoprecipitation assay
RNA precipitation assays were performed as previously described 21, 22 . Briefly, MB-231 cells transfected with a miR-34a mimic were used as control. MB-231 cells (7x10 5 cells/well) were seeded into 6-well plates and maintained overnight in RPMI 1640 medium, no folic acid (Life Technologies) supplemented with 10% fetal bovine serum (Sigma), 100U/mL penicillin and 100ug/mL streptomycin (Hyclone, GE Healthcare Life Sciences) at 37°C in 5% CO 2 . The next day, medium was replaced with 800 µL of fresh complete medium. Transfection of miR-34a mimic (Ambion, final concentration 6nM) was performed with Lipofectamine RNAimax (Life Technologies) by mixing 100 µL serum free medium (SFM) containing mir-34a mimic (Ambion) and 100 µL SFM with 7.5 µL of Lipofectamine RNAimax (Life Technologies), incubated at room temperature for 5 min and then added to the wells. Cells were incubated for 4 h at 37°C in 5% CO 2 and media was replaced with 2 mL of fresh complete medium. For FolamiR-34a or Fol-Nig-34a treatments, MB-231 cells (8x10 5 cells/well) in complete medium were seeded into 6-well plates containing FolamiR-34a or Fol-Nig-34a diluted in 1 mL serum free RPMI medium to a final concentration of 100 nM. After 24 h cells were put on ice, washed twice with ice cold PBS and immersed in 1 mL PBS. Cells were cross-linked at 400 mJ per cm 2 and then again at 200 mJ per cm 2 in an UV cross-linker (XL-1000, SpectroLinker). Cells were scraped directly into lysis buffer (1× PBS, 1% vol/vol NP40 substitute, 0.5% wt/vol sodium deoxycholate and 0.1% wt/vol SDS). Next, the lysates were centrifuged in a prechilled tabletop ultracentrifuge at 21,000 g for 20 min at 4°C. Cleared lysates were incubated with Dynabead Protein A beads (Life Technologies) prepared with 2A8 anti-AGO 21, 23 (Millipore, MABE56) or normal mouse IgG (Millipore, 12-371) for 90 min at 4°C, washed and resuspended as previously described 21 . RNA was isolated using Qiazol reagent (Qiagen) followed by ethanol precipitation. Reverse transcription was performed using the miRscript II RT kit (Qiagen) using the HiSpec buffer.
Real-time PCR was conducted using miScript SYBR Green PCR Kit (Qiagen) with the following primers: RNU6B (non-target RNA, Qiagen MiScript primer assay), let-7b-1 (positive control, Qiagen MiScript primer assay) and mir-34a (Qiagen MiScript primer assay). Real time PCR data was analyzed using the 2 -∆∆Ct method 24, 25 and expressed as fold enrichment.
Protein isolation and western blotting MB-231 cells were collected in RNA Later (Life Technologies) and stored at -80°C. Frozen cells were placed in 2 mL collection tubes containing radioimmunoprecipitation assay buffer (1 X phosphate-buffered saline, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 X protease inhibitor). Cells were incubated for 10 min on ice and centrifuged for 10 min at 4°C (20,000 g), supernatant was collected, 50 ug of protein was resolved on 12% TGX gels (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF) membranes. Revert Total Protein Staining kit (Licor) was used as protein loading control following the manufacturer's instructions. 2A8 anti-AGO (1:1000, Millipore, MABE56) primary antibody was used for Argonaute 2 detection. Protein detection was performed following incubation with secondary antibodies (Licor), membranes were washed and signal was acquired using Licor Odyssey CLX (Licor). protocol 19, 20 . Statistical analysis performed with Student's T-test,*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant. ANOVA and Bonferroni correction, (*, P < 0.1; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
Acknowledgements:
Folate receptor
Receptor mediated endocytosis
Gene modulation 
